Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guava Technologies Inc.

Division of EMD Millipore/Guava Technologies Inc.
www.guavatechnologies.com

Latest From Three Rivers Pharmaceuticals LLC

Start-Up Quarterly Statistics, Q4 2010

Biopharma, medical device and in vitro diagnostics start-ups brought in a total of $548 million in Q4 2010, a 30% drop from the previous quarter and a 24% decrease from Q4 2009. Six start-up acquisitions were completed - five in the biopharmaceutical industry and one diagnostic transaction. In the fourth quarter there were 27 start-up biopharma alliances covering a wide range of therapeutic categories, and fourteen of them involved large molecules.
BioPharmaceutical Medical Device

Deals Shaping the Medical Industry (12/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions

Waksal's Kadmon rapidly builds on hepatitis C franchise with Valeant deals

Kadmon Pharmaceuticals, Samuel Waksal's new venture, is moving quickly to strengthen its hepatitis C franchise.

Cardiovascular Cancer

Waksal's Kadmon acquires Three Rivers

Kadmon Pharmaceuticals, led by former ImClone CEO Dr Samuel Waksal, has acquired Three Rivers Pharmaceuticals, a privately held specialty pharma, for $100 million.

See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Medical Devices
    • Monitoring Equipment & Devices
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • EMD Millipore
  • Merck KGAA
  • Senior Management
  • David A King, PhD, VP, R&D & Operations
    Paul Wheeler, PhD, VP, Sales & Mktg.
  • Contact Info
  • Guava Technologies Inc.
    Phone: (510) 576-1400
    25801 Industrial Blvd.
    Hayward, CA 94545-2991
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register